Gilead Sciences (FRA:GIS) Cash Flow for Dividends: €-3,467 Mil (TTM As of Mar. 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €108.26
GF Value €81.25
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Cash Flow for Dividends?

Gilead Sciences FRA:GIS -0.79% 75 Cash Flow for Dividends is €-3,467 Mil as of Mar. 2026. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €81.25 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Gilead Sciences's cash flow for dividends for the three months ended in Mar. 2026 was €-900 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €-3,467 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Gilead Sciences's quarterly payment of dividends declined from Sep. 2025 (€-856 Mil) to Dec. 2025 (€-849 Mil) but then increased from Dec. 2025 (€-849 Mil) to Mar. 2026 (€-900 Mil).

Gilead Sciences's annual payment of dividends increased from Dec. 2023 (€-3,493 Mil) to Dec. 2024 (€-3,742 Mil) but then declined from Dec. 2024 (€-3,742 Mil) to Dec. 2025 (€-3,419 Mil).

Gilead Sciences Cash Flow for Dividends Related Terms

Gilead Sciences Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cash Flow for Dividends Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,190.43 -3,501.30 -3,492.85 -3,741.69 -3,418.56

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -934.25 -861.80 -856.26 -848.88 -899.60
FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3,467 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €-3,467 Mil mean?
Gilead Sciences (FRA:GIS) has a Cash Flow for Dividends of €-3,467 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Gilead Sciences and its competitors.
Is Gilead Sciences' Cash Flow for Dividends too high?
Gilead Sciences' current Cash Flow for Dividends is €-3,467 Mil. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Cash Flow for Dividends compare to PFE and AMGN?
Gilead Sciences' Cash Flow for Dividends of €-3,467 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Gilead Sciences and its competitors. Gilead Sciences's current Cash Flow for Dividends is €-3,467 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €81.25, compared to a current price of €108.26 — trading 33.2% above its estimated fair value. The current Cash Flow for Dividends is €-3,467 Mil. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Cash Flow for Dividends is €-3,467 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €108.26 is trading 33.2% above its estimated GF Value™ of €81.25. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Cash Flow for Dividends: €-3,467 Mil
  • GF Value™: €81.25 vs. price of €108.26 (33.2% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€108.26
Price
€81.25
GF Value